BlossomHill to present updated Phase 1/2 SOLARA trial data
BlossomHill Therapeutics will present updated Phase 1/2 SOLARA trial data for BH-30643, its macrocyclic OMNI-EGFR inhibitor, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
BLSM to present updated SOLARA Phase 1/2 trial data
BlossomHill Therapeutics will present updated data from its ongoing Phase 1/2 SOLARA trial of BH-30643 in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer.